De novo appearance of der(1;7)(q10;p10) is associated with leukemic transformation and unfavorable prognosis in essential thrombocythemia

Leukemia Research

Volumn 29, Issue 11, 2005, Pages 1247-1252

  Hsiao, Hui Hua ^a,b   Ito, Yoshikazu ^a   Sashida, Goro ^a   Ohyashiki, Junko H ^a   Ohyashiki, Kazuma ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chromosome aberrations; der(1 ; 7)(q10 ; p10); Essential thrombocythemia; Leukemic transformation

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; CYTOTOXIC AGENT; HYDROXYUREA;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTHEMIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 7; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; KARYOTYPING; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MYELOFIBROSIS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THROMBOCYTHEMIA, HEMORRHAGIC; TRANSLOCATION, GENETIC;

EID: 24744470485     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.03.011     Document Type: Article

References (24)

1. S. Murphy, P. Peterson, H. Iland, and J. Laszlo Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment Semin Hematol 34 1997 29 39
2. C. Rozman, M. Giralt, E. Feliu, D. Rubio, and M.T. Cortes Life expectancy of patients with chronic nonleukemic myeloproliferative disorders Cancer 67 1991 2658 2663
3. A. Hattori, R. Nagayama, K. Kishi, I. Fuse, M. Hanano, and S.I. Takizawa Primary thrombocythemia in Japan: a survey of 225 patients Leuk Lymphoma 4 1991 177 186
4. G. Finazzi, and T. Barui Treatment of essential thrombocythemia with special emphasis on leukemogenic risk Ann Hematol 78 1999 389 392
5. A. Tefferi, and S. Murphy Current opinion in essential thrombocythemia: pathogenesis, diagnosis, and management Blood Rev 15 2001 121 131
6. C.N. Harrison Current trends in essential thrombocythaemia Br J Haematol 117 2002 796 808
7. T. Barbui The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequel of therapy, or a combination of both? Semin Hematol 41 2004 15 17
8. V. De Sanctis, M.G. Mazzucconi, A. Spadea, M. Alfo, M. Mancini, and L. Bizzoni Long-term evaluation of 164 patients with essential thrombocythaemia treated with pipobroman: occurrence of leukaemic evolution Br J Haematol 123 2003 517 521
9. G. Finzzi, M. Ruggeri, F. Rodeghiero, and T. Barbui Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial Br J Haematol 110 2000 577 583
10. M.L. Randi, F. Fabris, and A. Girolami Second malignancies in patients with essential thrombocythaemia Br J Haematol 116 2002 923 924
11. F. Mertens, B. Johansson, S. Heim, U. Kristoffersson, and F. Mitelman Karyotypic patterns in chronic myeloproliferative disorders: report on 74 cases and review of the literature Leukemia 5 1991 214 220
12. Groupe francais de cytogenetique hematologique Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome Cancer Genet Cytogenet 32 1998 157 168
13. P. Bernasconi, M. Boni, P.M. Cavigliano, S. Calatroni, E. Brusamolino, and F. Passamonti Acute myeloid leukemia (AML) having evolved from essential thrombocythemia (ET): distinctive chromosome abnormalities in patients treated with pipobroman or hydroxyurea Leukemia 16 2002 2078 2083
14. K. Uozumi, N. Ohno, S. Shimotakahara, S. Suzuki, S. Takeuchi, and S. Hanada Trisomy 8 in enssential thrombocythemia in leukemic transformation Cancer Genet Cytogenet 116 2000 84 86
15. Y. Hirose, Y. Masaki, and S. Sugai Leukemic transformation with trisomy 8 in essential thrombocythemia: a report of four cases Eur J Haematol 68 2002 112 116
16. J.M.J.C. Scheres, T.W.J. Hustinx, J.P.M. Geraedts, C.H.W. Leeksma, and P.S. Meltzer Translocation 1;7 in hematologic disorders: a brief review of 22 cases Cancer Genet Cytogenet 18 1985 207 213
17. B. Pedersen Survival of patients with t(1;7)(p11;q11). Report of two cases and review of the literature Cancer Genet Cytogenet 60 1992 53 59
18. P. Willem, M. Pinto, and R. Bernstein Translocation t(1;7) revisited. Report of three further cases and review Cancer Genet Cytogenet 36 1998 45 54
19. S. Hayashi, H. Iwama, Y. Uchida, K. Kawakubo, Y. Inatomi, and M. Nagasu Essential thrombocythemia in transformation to acute leukemia (FAB-M0) as a natural history from myelofibrosis with t(1;7) Jpn J Clin Hematol 38 1997 445 447
20. D.E. Horsman, and D.K. Kalousek Acquired Robertsonian translocations in hematologic malignancy. A rare mechanism of clonal evolution Cancer Genet Cytogenet 45 1990 193 196
21. Y. Uesugi, K. Toba, K. Nikkuni, I. Fuse, T. Koike, and A. Shibata Essential thrombocythemia in transformation to smouldering megakaryoblastic leukemia with myelofibrosis Jpn J Clin Hematol 36 1995 1210 1216
22. J. Thiele, H.M. Kvasnicka, A. Schmitt-Graeff, R. Zankovich, and V. Diehl Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients Am J Hematol 70 2002 283 291
23. P.O. Andersson, B. Ridell, H. Wadenvik, and J. Kutti Leukemic transformation of essential thrombocythemia without previous cytoreductive treatment Ann Hematol 79 2000 40 42
24. Y. Sterkers, C. Preudhomme, J.L. Lai, J.L. Demor, M.T. Caulier, and E. Wattel Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion Blood 91 1998 616 622